Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study
Authors:
- Teruhisa SakamotoTSTeruhisa Sakamoto
- Mikiya KishinoMKMikiya Kishino
- Yuki MurakamiYMYuki Murakami
- Kozo MiyataniKMKozo Miyatani
- Takehiko HanakiTHTakehiko Hanaki
- Yuji ShishidoYSYuji Shishido
- Kyoichi KiharaKKKyoichi Kihara
- Tomoyuki MatsunagaTMTomoyuki Matsunaga
- Manabu YamamotoMYManabu Yamamoto
- Naruo TokuyasuNTNaruo Tokuyasu
- Yoshiyuki FujiwaraYFYoshiyuki Fujiwara
Open Access
- 24 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (21) , e38292
Abstract
This study aimed to investigate the prognostic relationship between relative dose intensity (RDI) of adjuvant S-1 chemotherapy and psoas muscle mass volume (PMV) in patients with resected pancreatic ductal adenocarcinoma. We enrolled 105 patients with histologically confirmed pancreatic ductal adenocarcinoma who had undergone pancreatectomy. Adjuvant S-1 chemotherapy was administered to 72 (68.6%) of the 105 patients and not to the remaining 33 patients. Patients who received adjuvant S-1 chemotherapy were stratified into high- and low-RDI groups by the cutoff value for RDI. Five-year overall survival (OS) and relapse-free survival (RFS) rates were significantly higher in the high- than in the low-RDI group. Similarly, both the 5-year OS and RFS rates were significantly greater among patients in the high-PMV group than among patients in the low-PMV group. The RDI was an independent prognostic factor in our study patients. Furthermore, patients who received adjuvant S-1 chemotherapy were stratified into 3 groups: those with both high RDI and high-PMV, Group A; those with either high RDI or high PMV (but not both), Group B; and those with both low RDI and low-PMV, group C. There were statistically significant differences in 5-year OS and RFS between 3 patient groups (5-year overall survival: P = .023, 5-year relapse-free survival: P = .001). The area under the curve for the combination of RDI and PMV (0.674) was greater than that for RDI alone (0.645). A sufficient dosage of adjuvant S-1 chemotherapy is important in improving survival of patients with resected pancreatic ductal adenocarcinoma. A combination of RDI and PMV may predict the prognosis of patients with resected pancreatic ductal adenocarcinoma more effective than RDI alone.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patientsBritish Journal of Cancer, 2020
- Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective studyBMC Cancer, 2019
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerNew England Journal of Medicine, 2018
- Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclinesOncotarget, 2018
- Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2018
- Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C‐SCANS studyCancer, 2017
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialThe Lancet, 2017
- Regulation of muscle growth and regeneration by the immune systemNature Reviews Immunology, 2017
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)The Lancet, 2016
- Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal AdenocarcinomaAnnals of Surgical Oncology, 2016